TAFNAT-TENOFOVIR-ALAFENAMIDE-25MG
TAFNAT 25MG
Drug profile for Tafnat tablet
Tafnat tablets are primarily used in hepatitis infection condition, is in chronic stage.
Tafnat 25MG tablets are only used by the patients who are having a valid prescription
Tafnat tablets are containing an anti-viral agent known as Tenofovir Alafenamide which may not cure the infection but may suppress the growth of virus.
Trade name: Tafnat
Active component: Tenofovir Alafenamide
Strength: 25mg
Mfg: natco pharma
Pack: 30 tablets in a container
Category: Anti-hepaciviral activity
Prescribing information of Tafnat:
The most frequently used anti-viral agent like Tenofovir Alafenamide is primarily indicated for the treatment of chronic hepatitis B viral infection occurred in adults’ patient with compensated liver damage.
Mechanism of Tafnat:
Tafnat worked in the body by some component incorporates;
For the most part Tafnat containing tenofovir Alafenamide is a prodrug which is changed over into dynamic frame in-vivo
Tenofovir Alafenamide has cell penetrability property which is lipophilic in nature, infiltrates into hepatocytes by latent dissemination strategy and additionally by hepatic return transporters OATP1B1 and OATP1B3
In-vivo, tenofovir Alafenamide is changed into tenofovir a parent compound by experiencing hydrolysis with the chemical carboxylesterase 1 which is happen in hepatocytes cell
This dynamic frame tenofovir is phosphorylated into tenofovir diphosphate by cell kinase compounds
TAF has pharmacologically dynamic compound known as tenofovir diphosphate which is in charge of viral multiplication denial by means of imbuing into infection DNA with the assistance of turnaround transcriptase chemical which causes viral DNA chain end
Absorption:
Maximum plasma concentration time of TAF 0.48 hours
Distribution:
TAF is largely bound to human plasma protein at 80%
Protein binding data occurs in vivo
The blood plasma ratio of TAF is 1.0
Metabolism:
The metabolism of TAF occurs with the help of;
Carboxyl esterase 1
Cathepsin A
CYP3A
 |
| Tafnat 25MG |
Excretion:
Nearly 80% of TAF get metabolized and reaches its half life at 0.51 hour
<1% of metabolite released through urine
31.7% excreted via feces
When to take the Tafnat tablets:
Tafnat tablets should be taken with food
Dosage regimens of Tafnat:
Before initiate the treatment with Tafnat tablets, patients must be investigated whether they are suspected with HIV 1 infection or not.
The suggested dosage of Tafnat 25mg should be administered as a single dose.
In both mild to moderate liver and kidney impaired patients, dosage adjustment should not be allowed; whereas severe conditions, Tafnat not recommended.
Tafnat caused side effects:
The most serious adverse effects;
Serious exacerbation of hepatitis B infection
Out breaking or worsening of renal damage
Lactic acidosis
Hepatomegaly with steatosis
Common side effects;
Fatigue
Headache
Cough
Back pain
Nausea
Abdominal pain
Loss of bone mineral density
Glycosuria
Increase in lipase & amylase
Increasing in serum lipids
Drug- drug interaction of Tafnat:
Tafnat tablets with P-gp or BCRP inhibiting drugs, causes variation in absorption of TAF; this may leads to adverse effects.
Tafnat tablets with P gp or BCRP inducing drugs causes depletion of absorption of TAF leads to increasing the concentration of TAF
Tafnat tablets with renal function reducing drugs may leads to increasing the concentration and causes serious adverse effects
Tafnat tablet combined with anti-convulsants leads to decreasing the effect of concentration of TAF
Tafnat tablet combined with anti-mycobacterials causes reducing the effect of concentration of TAF
Tafnat 25MG tablets concomitant use of herbal product like st, John’s wort, causes decreasing the TAF concentration.
Food drug interaction of Tafnat:
Minor food drug interaction may occur; alcohol containing food items should not be suggested.
Consult with physician about the dietary.
Possible contraindications of Tafnat:
No specific contraindication occurs, if some patients may contraindicate to TAF causes anaphylactic reactions.
Safety measures:
Aggravation of hepatitis B infection: Check the patient history before starting the treatment
Exposure of advancement of HIV-1 resistance: Due to this condition, Tafnat tablets are not suggested for HIV-1 infections
New commencement of renal damage: To avoid concomitant use of Tafnat with renal function depleting drugs
Lactic acidosis or hepatomegaly with steatosis: Stop the therapy with Tafnat25MG
Pregnancy and lactation:
Tafnat tablets are probably used in pregnancy conditions, only after knowing the risk of the product associated to fetus.
Breast feeding should not be suggested.
Storage and handling:
Tafnat tablet container should be kept at below 30oC
Protect the container from heat, moisture & heat
Missed dose:
In case of missed dose, get advice from medical practitioner and their instruction; otherwise avoid the missed dose and follow the regular schedule.
Over dosage:
If over dosage occurs during the therapy;
Provide the patients with supportive measures
Monitor the signs & symptoms
Hemodialysis is done, to eliminate the TAF content with the range of 54%.
Comments
Post a Comment